Can thymosin β4 and soluble CD163 be used as biomarkers of the prognosis in acute on chronic liver failure?

J Gastrointestin Liver Dis. 2022 Mar 20;31(1):143-145. doi: 10.15403/jgld-4161.
No abstract available

Publication types

  • Letter

MeSH terms

  • Acute-On-Chronic Liver Failure*
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • Humans
  • Prognosis
  • Receptors, Cell Surface
  • Thymosin*

Substances

  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • CD163 antigen
  • Receptors, Cell Surface
  • thymosin beta(4)
  • Thymosin